
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8448539/publications.pdf

Version: 2024-02-01



Ονίν Μίν Κον

#	Article	IF	CITATIONS
1	Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial. Thorax, 2022, 77, 950-959.	2.7	7
2	Broadening symptom criteria improves early case identification in SARS-CoV-2 contacts. European Respiratory Journal, 2022, 60, 2102308.	3.1	7
3	Monitoring prolongation of QT interval in patients with multidrug-resistant tuberculosis and non-tuberculous mycobacterium using mobile health device AliveCor. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022, 26, 100293.	0.6	1
4	BTS clinical statement for the diagnosis and management of ocular tuberculosis. BMJ Open Respiratory Research, 2022, 9, e001225.	1.2	5
5	Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance. BMC Infectious Diseases, 2022, 22, 349.	1.3	9
6	Effectiveness of nationwide programmatic testing and treatment for latent tuberculosis infection in migrants in England: a retrospective, population-based cohort study. Lancet Public Health, The, 2022, 7, e305-e315.	4.7	17
7	Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 2. Ophthalmology, 2021, 128, 277-287.	2.5	46
8	Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. Journal of Allergy and Clinical Immunology, 2021, 147, 694-703.e12.	1.5	23
9	Insights into the molecular pathogenesis of ocular tuberculosis. Tuberculosis, 2021, 126, 102018.	0.8	7
10	Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. European Heart Journal, 2021, 42, 1866-1878.	1.0	274
11	Transcriptomic signatures for diagnosing tuberculosis in clinical practice: a prospective, multicentre cohort study. Lancet Infectious Diseases, The, 2021, 21, 366-375.	4.6	26
12	New technologies for diagnosing active TB: the VANTDET diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2021, 8, 1-160.	0.9	2
13	Symptomatic, biochemical and radiographic recovery in patients with COVID-19. BMJ Open Respiratory Research, 2021, 8, e000908.	1.2	10
14	A conceptual framework to accelerate the clinical impact of evolving research into long COVID. Lancet Infectious Diseases, The, 2021, 21, 756-757.	4.6	12
15	Review: The Nose as a Route for Therapy. Part 2 Immunotherapy. Frontiers in Allergy, 2021, 2, 668781.	1.2	5
16	Defining the Role of Cellular Immune Signatures in Diagnostic Evaluation of Suspected Tuberculosis. Journal of Infectious Diseases, 2021, , .	1.9	2
17	Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease. Microorganisms, 2021, 9, 2220.	1.6	7
18	Genomic signatures of pre-resistance in Mycobacterium tuberculosis. Nature Communications, 2021, 12, 7312.	5.8	33

#	Article	IF	CITATIONS
19	The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis. Ocular Immunology and Inflammation, 2020, 28, 38-48.	1.0	44
20	Tubercular Uveitis: Nuggets from Collaborative Ocular Tuberculosis Study (COTS)-1. Ocular Immunology and Inflammation, 2020, 28, 8-16.	1.0	25
21	Developing a pathway for the diagnosis and management of ocular tuberculosis. The pan-LOndon Ocular tuberculosis Pathway—LOOP. Eye, 2020, 34, 805-808.	1.1	13
22	A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK. Journal of Infection, 2020, 80, 38-41.	1.7	8
23	A postgraduate qualification in tuberculosis—Message in a bottle. International Journal of Infectious Diseases, 2020, 92, S100-S102.	1.5	1
24	The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings. Ocular Immunology and Inflammation, 2020, , 1-11.	1.0	8
25	Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. European Respiratory Journal, 2019, 54, 1900982.	3.1	14
26	Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza. European Respiratory Journal, 2019, 54, 1900949.	3.1	22
27	An update on multidrug-resistant tuberculosis. Clinical Medicine, 2019, 19, 135-139.	0.8	19
28	Time to diagnosis of tuberculosis is greater in older patients: a retrospective cohort review. ERJ Open Research, 2019, 5, 00228-2018.	1.1	35
29	Clinical utility of existing and second-generation interferon-Î ³ release assays for diagnostic evaluation of tuberculosis: an observational cohort study. Lancet Infectious Diseases, The, 2019, 19, 193-202.	4.6	47
30	The Collaborative Ocular Tuberculosis Study (COTS)-1 Report 3: Polymerase Chain Reaction in the Diagnosis and Management of Tubercular Uveitis: Global Trends. Ocular Immunology and Inflammation, 2019, 27, 465-473.	1.0	48
31	Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection. Journal of Clinical Investigation, 2019, 130, 523-538.	3.9	42
32	Prognostic value of interferon-Î ³ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 1077-1087.	4.6	135
33	Global Variations and Challenges With Tubercular Uveitis in the Collaborative Ocular Tuberculosis Study. , 2018, 59, 4162.		50
34	Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health Technology Assessment, 2018, 22, 1-96.	1.3	24
35	Stratification of Latent Mycobacterium tuberculosis Infection by Cellular Immune Profiling. Journal of Infectious Diseases, 2017, 215, 1480-1487.	1.9	54
36	A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-γ and IFN-λ) and Type 2 Inflammation (IL-5 and IL-13). EBioMedicine, 2017, 19, 128-138.	2.7	102

#	Article	IF	CITATIONS
37	Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)–1. JAMA Ophthalmology, 2017, 135, 1318.	1.4	129
38	Innate activation of human primary epithelial cells broadens the host response to Mycobacterium tuberculosis in the airways. PLoS Pathogens, 2017, 13, e1006577.	2.1	48
39	Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis. Survey of Ophthalmology, 2016, 61, 628-653.	1.7	86
40	Viral hepatitis prevalence in patients with active and latent tuberculosis. World Journal of Gastroenterology, 2015, 21, 8920.	1.4	20
41	RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nature Communications, 2015, 6, 10224.	5.8	237
42	Screening tests for tuberculosis before starting biological therapy. BMJ, The, 2015, 350, h1060-h1060.	3.0	12
43	The national TB strategy: jointly taking responsibility for TB control?. Thorax, 2015, 70, 211-212.	2.7	1
44	Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approach. BMJ Open, 2015, 5, e005750-e005750.	0.8	1
45	Risk factors for the misdiagnosis of tuberculosis in the UK, 2001–2011. European Respiratory Journal, 2015, 46, 564-567.	3.1	12
46	Screening for latent tuberculosis before tumour necrosis factor antagonist therapy. European Respiratory Journal, 2015, 45, 1510-1512.	3.1	4
47	Vitamin D deficiency and TB disease phenotype. Thorax, 2015, 70, 1171-1180.	2.7	31
48	Breath metabolite response to major upper gastrointestinal surgery. Journal of Surgical Research, 2015, 193, 704-712.	0.8	5
49	Nasal Lipopolysaccharide Challenge and Cytokine Measurement Reflects Innate Mucosal Immune Responsiveness. PLoS ONE, 2015, 10, e0135363.	1.1	19
50	Performance of Xpert MTB/RIF in the Diagnosis of Tuberculous Mediastinal Lymphadenopathy by Endobronchial Ultrasound. Annals of the American Thoracic Society, 2014, 11, 392-396.	1.5	42
51	Time for a preventative strategy for TB in the UK: further evidence for new entrant screening in primary care. Thorax, 2014, 69, 305-306.	2.7	5
52	GeneXpert® MTB/RIF in low prevalence settings: A UK laboratory perspective. Journal of Infection, 2014, 69, 199-200.	1.7	3
53	Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax, 2014, 69, 240-246.	2.7	121
54	IL-33–Dependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations <i>In Vivo</i> . American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1373-1382.	2.5	500

#	Article	IF	CITATIONS
55	ESX1-dependent fractalkine mediates chemotaxis and Mycobacterium tuberculosis infection in humans. Tuberculosis, 2014, 94, 262-270.	0.8	10
56	Smoking Cessation in COPD Causes a Transient Improvement in Spirometry and Decreases Micronodules on High-Resolution CT Imaging. Chest, 2014, 145, 1006-1015.	0.4	18
57	Exhaled breath acetone for therapeutic monitoring in pneumonia using selected ion flow tube mass spectrometry (SIFT-MS). Analytical Methods, 2013, 5, 3807.	1.3	15
58	Primary nodal anthracosis identified by EBUS-TBNA as a cause of FDG PET/CT positive mediastinal lymphadenopathy. Respiratory Medicine Case Reports, 2013, 10, 48-52.	0.2	13
59	Outgrowth of the Bacterial Airway Microbiome after Rhinovirus Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1224-1231.	2.5	329
60	Undetected Multidrug-Resistant Tuberculosis Amplified by First-line Therapy in Mixed Infection. Emerging Infectious Diseases, 2013, 19, 1138-1141.	2.0	36
61	Do we need bacteriological confirmation of cure in uncomplicated tuberculosis?: Table 1–. European Respiratory Journal, 2013, 42, 860-863.	3.1	4
62	Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis. Thorax, 2013, 68, 230-239.	2.7	65
63	Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy. Thorax, 2013, 68, 955-961.	2.7	29
64	TLR3, TLR4 and TLRs7–9 Induced Interferons Are Not Impaired in Airway and Blood Cells in Well Controlled Asthma. PLoS ONE, 2013, 8, e65921.	1.1	39
65	A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 653-659.	2.5	44
66	Rhinovirus 16–induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients. Journal of Allergy and Clinical Immunology, 2012, 129, 1506-1514.e6.	1.5	190
67	Sarcoidosis and Tuberculosis Cytokine Profiles: Indistinguishable in Bronchoalveolar Lavage but Different in Blood. PLoS ONE, 2012, 7, e38083.	1.1	31
68	The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. Journal of Allergy and Clinical Immunology, 2011, 128, 800-807.e9.	1.5	59
69	Post-bronchoscopy sputum: Improving the diagnostic yield in smear negative pulmonary TB. Respiratory Medicine, 2011, 105, 1726-1731.	1.3	19
70	Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infectious Diseases, The, 2011, 11, 435-444.	4.6	187
71	International Spread of MDR TB from Tugela Ferry, South Africa. Emerging Infectious Diseases, 2011, 17, 2035-7.	2.0	22
72	Don't blame the bones!. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 191-191.	3.3	1

#	Article	IF	CITATIONS
73	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy, 2011, 66, 1815-1820.	1.3	80
74	Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study. Thorax, 2011, 66, 889-893.	2.7	166
75	A mycolic acid–specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. Journal of Clinical Investigation, 2011, 121, 2493-2503.	3.9	106
76	Expression of Transient Receptor Potential C6 Channels in Human Lung Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 296-304.	1.4	55
77	Enumeration of Functional T-Cell Subsets by Fluorescence-Immunospot Defines Signatures of Pathogen Burden in Tuberculosis. PLoS ONE, 2010, 5, e15619.	1.1	74
78	Anticholinergic Bronchodilators. , 2009, , 615-626.		0
79	Optimized Dialysis and Protease Inhibition of Sputum Dithiothreitol Supernatants. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 132-141.	2.5	26
80	Rapid Effect of Inhaled Ciclesonide in Asthma. Chest, 2008, 134, 740-745.	0.4	39
81	Reduction of persistent air leak with endoscopic valve implants. Thorax, 2007, 62, 830-833.	2.7	49
82	Pulmonary Infection with <i>Cryptococcus neoformans</i> in the Face of Underlying Sarcoidosis. Respiration, 2007, 74, 462-466.	1.2	12
83	A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: Upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulmonary Pharmacology and Therapeutics, 2007, 20, 52-59.	1.1	48
84	The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-α in Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 753-762.	2.5	270
85	Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. Journal of Allergy and Clinical Immunology, 2006, 118, 641-648.	1.5	134
86	Bronchoscopic Techniques for Treating Emphysema. Clinical Pulmonary Medicine, 2006, 13, 263-270.	0.3	0
87	The cardiopulmonary effects of physical restraint in subjects with chronic obstructive pulmonary disease. Journal of Clinical Forensic and Legal Medicine, 2005, 12, 133-136.	0.9	13
88	Diagnosis and treatment of tuberculosis: latest developments and future priorities. Annals of Research Hospitals, 0, 1, 1-1.	0.0	14